rupiya.io
⠋Loading...
0%
❯ Parsing revenue segments...
Alkem Laboratories Ltd is a Drug Manufacturers - Specialty & Generic company listed on NSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Alkem Laboratories Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹3,113 Cr | ₹3,674 Cr | ₹4,905 Cr | |||||||||
| Expenses | ₹2,700 Cr | ₹3,248 Cr | ₹4,038 Cr | |||||||||
| Operating Profit | ₹413 Cr | ₹427 Cr | ₹866 Cr | |||||||||
| OPM % | 13.0% | 12.0% | 18.0% | |||||||||
| Other Income | ₹162 Cr | ₹176 Cr | ₹227 Cr | |||||||||
| Depreciation | ₹52 Cr | ₹71 Cr | ₹93 Cr | |||||||||
| Interest | ₹93 Cr | ₹81 Cr | ₹71 Cr | |||||||||
| Profit Before Tax | ₹430 Cr | ₹451 Cr | ₹928 Cr | |||||||||
| Tax | ₹430 Cr | ₹451 Cr | ₹928 Cr | |||||||||
| Net Profit | ₹435 Cr | ₹392 Cr | ₹752 Cr | |||||||||
| EPS (₹) | 364.1 | 32.8 | 62.0 | |||||||||
| Dividend Payout % | 5% | 12% | 20% |
Register free to see 9 more years.
| Quarter | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | ₹3,041 Cr | ₹2,903 Cr | ₹2,968 Cr | ₹3,440 Cr | ||||||||
| Expenses | ₹2,442 Cr | ₹2,549 Cr | ₹2,579 Cr | ₹2,693 Cr | ||||||||
| Operating Profit | ₹599 Cr | ₹353 Cr | ₹389 Cr | ₹747 Cr | ||||||||
| OPM % | 20.0% | 12.0% | 13.0% | 22.0% | ||||||||
| Depreciation | ₹78 Cr | ₹78 Cr | ₹72 Cr | ₹74 Cr | ||||||||
| Interest | ₹27 Cr | ₹29 Cr | ₹30 Cr | ₹30 Cr | ||||||||
| Net Profit | ₹460 Cr | ₹68 Cr | ₹288 Cr | ₹615 Cr | ||||||||
| EPS (₹) | 38.0 | 5.9 | 24.0 | 51.9 |
Register free to see 8 more quarters.
| Period | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹12 Cr | ₹24 Cr | ₹24 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹2,567 Cr | ₹2,975 Cr | ₹3,668 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹1,128 Cr | ₹1,306 Cr | ₹658 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹604 Cr | ₹986 Cr | ₹1,184 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹4,311 Cr | ₹5,291 Cr | ₹5,534 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹1,170 Cr | ₹1,374 Cr | ₹1,450 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹588 Cr | ₹481 Cr | ₹509 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹2,553 Cr | ₹3,325 Cr | ₹3,403 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹4,311 Cr | ₹5,291 Cr | ₹5,534 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Register free to see 9 more years.
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2015 | ₹290 Cr | ₹353 Cr | ₹-600 Cr | — |
| Mar 2016 | ₹325 Cr | ₹-235 Cr | ₹-52 Cr | — |
| Mar 2017 | ₹726 Cr | ₹205 Cr | ₹-927 Cr | — |
| Mar 2018 | ||||
| Mar 2019 | ||||
| Mar 2020 | ||||
| Mar 2021 | ||||
| Mar 2022 | ||||
| Mar 2023 | ||||
| Mar 2024 | ||||
| Mar 2025 |
Register free to see 9 more years.
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.